These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

825 related items for PubMed ID: 19201831

  • 1. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
    Li D, Qian L, Chen C, Shi M, Yu M, Hu M, Song L, Shen B, Guo N.
    J Immunol; 2009 Feb 15; 182(4):1799-809. PubMed ID: 19201831
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Collagen and major histocompatibility class II expression in mesenchymal cells from CIITA hypomorphic mice.
    Xu Y, McDonald J, Perloff E, Butticè G, Schreiber BM, Smith BD.
    Mol Immunol; 2007 Mar 15; 44(7):1709-21. PubMed ID: 16982097
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. IL-1 beta inhibits IFN-gamma-induced class II MHC expression by suppressing transcription of the class II transactivator gene.
    Rohn W, Tang LP, Dong Y, Benveniste EN.
    J Immunol; 1999 Jan 15; 162(2):886-96. PubMed ID: 9916712
    [Abstract] [Full Text] [Related]

  • 7. Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription Implication of CIITA in tumor and metastasis development.
    Shi B, Vinyals A, Alia P, Broceño C, Chen F, Adrover M, Gelpi C, Price JE, Fabra A.
    Int J Biochem Cell Biol; 2006 Jan 15; 38(4):544-62. PubMed ID: 16343978
    [Abstract] [Full Text] [Related]

  • 8. Regulation of MHC class II expression in glioma cells by class II transactivator (CIITA).
    Takamura Y, Ikeda H, Kanaseki T, Toyota M, Tokino T, Imai K, Houkin K, Sato N.
    Glia; 2004 Mar 15; 45(4):392-405. PubMed ID: 14966870
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
    Walter W, Lingnau K, Schmitt E, Loos M, Maeurer MJ.
    Br J Cancer; 2000 Nov 15; 83(9):1192-201. PubMed ID: 11027433
    [Abstract] [Full Text] [Related]

  • 13. The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in myelomonocytic cells.
    De Lerma Barbaro A, Procopio FA, Mortara L, Tosi G, Accolla RS.
    Eur J Immunol; 2005 Feb 15; 35(2):603-11. PubMed ID: 15627980
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Class II transactivator promoter activity is suppressed through regulation by a trophoblast noncoding RNA.
    Geirsson A, Paliwal I, Lynch RJ, Bothwell AL, Hammond GL.
    Transplantation; 2003 Jul 27; 76(2):387-94. PubMed ID: 12883198
    [Abstract] [Full Text] [Related]

  • 18. Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain.
    Itoh-Lindstrom Y, Piskurich JF, Felix NJ, Wang Y, Brickey WJ, Platt JL, Koller BH, Ting JP.
    J Immunol; 1999 Sep 01; 163(5):2425-31. PubMed ID: 10452977
    [Abstract] [Full Text] [Related]

  • 19. Revisiting the specificity of the MHC class II transactivator CIITA in vivo.
    Otten LA, Leibundgut-Landmann S, Huarte J, Kos-Braun IC, Lavanchy C, Barras E, Borisch B, Steimle V, Acha-Orbea H, Reith W.
    Eur J Immunol; 2006 Jun 01; 36(6):1548-58. PubMed ID: 16703565
    [Abstract] [Full Text] [Related]

  • 20. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
    Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML, Ostrand-Rosenberg S.
    Cancer Res; 2006 Jan 15; 66(2):1147-54. PubMed ID: 16424052
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.